These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23514793)

  • 1. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis.
    Wang E; Chen Y
    Retina; 2013; 33(7):1375-92. PubMed ID: 23514793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.
    Lai TY; Luk FO; Lee GK; Lam DS
    Eye (Lond); 2012 Jul; 26(7):1004-11. PubMed ID: 22595908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
    Wakabayashi T; Ikuno Y; Gomi F
    Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
    Yoon JU; Byun YJ; Koh HJ
    Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
    Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A
    Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia.
    Cohen SY
    Retina; 2009 Sep; 29(8):1062-6. PubMed ID: 19734760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factor for myopic choroidal neovascularization.
    Ng DS; Kwok AK; Chan CW
    Clin Exp Ophthalmol; 2012; 40(1):e98-e110. PubMed ID: 21902785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials.
    Dong L; Li G; Song Z; Cheng X; Bai J; Zhang C
    BMJ Open; 2023 Jul; 13(7):e067921. PubMed ID: 37474162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
    Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
    Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration.
    Chen L; Miller JW; Vavvas D; Kim IK
    Retina; 2011 Nov; 31(10):2078-83. PubMed ID: 21691258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study.
    Li S; Ding X; Sun L; Zhao X; Zhang A; Lyu C; Liu B; Zhang J; Jin C; Lu L
    Clin Exp Ophthalmol; 2019 Mar; 47(2):250-258. PubMed ID: 30345611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.
    Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T
    Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome.
    Nielsen JS; Fick TA; Saggau DD; Barnes CH
    Retina; 2012 Mar; 32(3):468-72. PubMed ID: 21817958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
    Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
    Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
    Gabrielle PH; Nguyen V; Creuzot-Garcher C; Miguel L; Alforja S; Sararols L; Casaroli-Marano RP; Zarranz-Ventura J; Gillies M; Arnold J; Barthelmes D
    Acta Ophthalmol; 2022 Feb; 100(1):e288-e296. PubMed ID: 33960115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
    Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
    Kung YH; Wu TT; Huang YH
    Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry.
    Willis J; Morse L; Vitale S; Parke DW; Rich WL; Lum F; Cantrell RA
    Ophthalmology; 2017 Jul; 124(7):935-943. PubMed ID: 28372860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.